Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia and affects
approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has …

Abstract Purpose of Review Acute myeloid leukemia (AML) in children remains a
challenging disease to cure with suboptimal outcomes particularly when compared to the …

The outcome for children with acute myeloid leukemia (AML) has improved significantly over
the past 30 years, with complete remission and overall survival rates exceeding 90 and …

Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the
past decades, from nearly no child surviving to a present probability of cure of approximately …

Acute myeloid leukemia is a heterogeneous disease that accounts for approximately 20% of
acute leukemias in children and adolescents. Despite the lack of targeted therapy for most …

Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal
transformation of hematopoietic precursors through the acquisition of chromosomal …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to~ 70%, due to …

Although acute myeloid leukaemia (AML) has long been recognized for its morphological
and cytogenetic heterogeneity, recent high‐resolution genomic profiling has demonstrated a …

Purpose We review recent advances in the biologic understanding and treatment of
childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify …